Our Values

Our personal values are our corporate values

At Athenex Oncology, we believe our behavior defines our culture, both internally and with our customers. That’s why we align our corporate values with our personal values. Because our values are more than just words on a page…they are what you can expect from us.

  • COMMITMENT TO PATIENT CARE
    • Everything we do, we do in the service of patients. Athenex Oncology is dedicated to supporting patients and the wider oncology community throughout the entire cancer journey, providing solutions that change lives and outcomes.
      Learn more >
  • HIGHER STANDARDS
    • We strive for excellence in everything we do. Shortcuts won’t do. Our goal is to ensure safe, effective products that address real and significant unmet needs for patients with cancer. No lowering the bar. No compromises. No one should settle for less.
  • COLLABORATIVE NATURE
    • Improving patient care takes a village—from scientists to health care providers, patients, and advocacy. We realize that the cancer journey impacts a wide range of individuals and to improve the path forward, we need to be on it together.
  • PIONEERING SPIRIT
    • Our passion is discovering solutions to overcome challenges with current cancer treatments. We are never satisfied with the status quo. Nothing can get in the way of progress as we tirelessly explore new ways to improve patient care.
  • MEANINGFUL RESULTS
    • Results matter. That’s why we work closely with patients and the oncology community to define “meaningful results.” What matters to us is what matters to them. Because anyone can produce results…we make sure we produce real results to make a real difference.

Leadership

Meet the Athenex Oncology team

Johnson Lau, MD

Chief Executive Officer & Board Chairman

Johnson has served as Chairman of the Board of Athenex since its inception and assumed the role of CEO in 2011. He is a successful pharmaceutical executive who brings extensive leadership experience to Athenex. While he was Chairman and CEO of Ribapharm, he launched the second largest biotech IPO in U.S. history. He has served as the Head of Worldwide Research and Development for ICN Pharmaceuticals and was the Senior Director of Antiviral Therapy at Schering-Plough. Johnson received his medical degree from the University of Hong Kong and is also a Fellow of the Royal College of Physicians.

Jeffrey Yordon

Chief Operating Officer & President

Jeffrey has held multiple senior management positions in the pharmaceutical industry over the past 48 years. Prior to joining Athenex, he was Founder, Chairman, and CEO of Sagent Pharmaceuticals; COO of American Pharmaceutical Partners; CEO of Faulding Pharmaceuticals; CEO and Founder of YorPharm; and COO of Gensia Pharmaceuticals. Jeffrey has successfully taken four companies public, all of which sold for significant returns for his shareholders.

Rudolf Kwan, MD

Chief Medical Officer

Rudolf has had a successful career in the pharmaceutical industry with over 20 years of experience in global clinical development and operations. Before joining Athenex, he served dual roles at Schering-Plough as vice president and regional head of Asia Pacific Global Clinical Operations and vice president of Global Clinical Development, CNS.

Timothy Cook

Senior Vice President, Global Oncology

Tim joined Athenex in July of 2018 as SVP of Global Oncology. In this role, he will lead the global launch efforts of oral paclitaxel and the rest of the innovative oncology pipeline. Tim began his oncology career with Bristol-Myers Squibb where he helped launch Taxol as an oncology sales professional. He joined Lilly Oncology in 2000, where he became the vice president of the North America Oncology Business Unit.

David Cutler, MD

Deputy Chief Medical Officer, Biologics and Cell Therapy

David brings significant scientific and managerial expertise to Athenex in the field of translational pharmacology and clinical research. Prior to joining Athenex, he held leadership positions at Merck Research Laboratories and Schering-Plough Research Institute in the Department of Experimental Medicine.

David received his medical degree from the College of Medicine of the University of Saskatchewan, and is board certified in Internal Medicine and Endocrinology and Metabolism, and is a Fellow of the Royal College of Physicians of Canada.

Igoni Dokubo, MD

Head, Medical Affairs

Igoni joined Athenex Pharmaceutical Division in July 2016. He is responsible for bringing medical- and clinical-based product insights to the company and members of the health care system. He provides scientific and clinical pharmacovigilance and drug safety expertise with a focus on the identification, evaluation, and management of safety risks for all of the company’s marketed products and developmental programs. Prior to joining Athenex, Igoni served as the medical director of Sagent Pharmaceuticals Inc., where he provided medical and clinical inputs and strategies for new corporate business development projects.

Athenex Oncology is a US-based biopharmaceutical company with a global presence. We are fiercely focused on developing novel cancer therapies that improve clinical outcomes and support patients’ well-being. Because the oncology community doesn’t just treat cancer…they treat patients who are mothers, fathers, sons, daughters, and friends.

News & Updates

Learn about what’s new

We are proud to share with you our latest efforts and scientific breakthroughs in the fight against cancer.

Press Releases

Athenex Oncology launches Facing MBC Together campaign to address isolation for people living with metastatic breast cancer

BUFFALO, N.Y. and CHICAGO, IL., June 13, 2020 – Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today announced that Athenex Oncology, a U.S. based division of Athenex, launched Facing MBC Together – a public education and patient support campaign that addresses isolation for people living with metastatic breast cancer (MBC)…

Read more >

Athenex Announces European Commission Grants Orphan Designations for Paclitaxel and Encequidar for the Treatment of Soft Tissue Sarcoma

BUFFALO, N.Y., Oct. 30, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has received Orphan…

Read more >

Athenex Announces Progress Update from Partner Almirall on Tirbanibulin Ointment

BUFFALO, N.Y., Oct. 28, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced a progress update from partner…

Read more >

Athenex Announces Initiation of Phase I Clinical Study in China of KX2-361 Oral by Partner Guangzhou Xiangxue Pharmaceutical

BUFFALO, N.Y., Sept. 11, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that its partner, Guangzhou…

Read more >

Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer

Study met primary endpoint showing statistically significant improvement in overall response rate for oral paclitaxel and encequidar (Oral Paclitaxel) compared to IV paclitaxel based on intention-to-treat (ITT) analysis Strong trend in progression-free survival (PFS) and overall survival (OS) of…

Read more >

SHOW MORE

Athenex, Inc. Announces Second Quarter 2019 Financial Results, Positive Phase III Results on Oral Paclitaxel plus Encequidar and Increased Product Sales Guidance

Positive Phase III results of Oral Paclitaxel show statistically significant improvement in overall response rate in metastatic breast cancer Company is preparing two NDA submissions following successful Phase III studies announced within the last twelve months Expanded clinical pipeline with…

Read more >

Athenex Provides an Update Regarding the Vasopressin Case

BUFFALO, N.Y., Aug. 02, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that the U.S…

Read more >

Athenex Announces U.S. FDA Allowance of Investigational New Drug Application for PT01 (Pegtomarginase)

BUFFALO, N.Y., June 24, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that the U.S…

Read more >

Athenex and PharmaEssentia Announce Positive Early Signals of Clinical Activity of KX2-391 (INN: tirbanibulin) in Patients with Psoriasis

BUFFALO, N.Y. and TAIPEI, Taiwan , June 06, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, and PharmaEssentia…

Read more >

Athenex Announces Promising Early and Complete Response Data from a Clinical Study of Oraxol in Cutaneous Angiosarcoma

Preliminary data show rapid, visible response to Oraxol monotherapy in the first seven subjects, including three complete responses BUFFALO, N.Y., May 03, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and…

Read more >

Athenex Announces Xiangxue Life Sciences Receives IND Allowance from China’s National Medical Products Administration for Cancer Immunotherapy Drug Candidate

This company-sponsored IND allows Xiangxue Life Sciences (XLifeSc) to proceed to the next stage of clinical studies in China Encouraging positive clinical safety and efficacy signals were observed in preliminary investigator-initiated pilot studies in China Athenex is XLifeSc’s partner (ex- China )…

Read more >

Athenex Regains Rights to KX2-391 in China

BUFFALO, N.Y., March 07, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that upon Athenex’s request…

Read more >

Athenex Announces Completion of Target Enrollment in the Oraxol Phase III Study

BUFFALO, N.Y., Jan. 09, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that target enrollment of 360…

Read more >

SHOW LESS

Upcoming Events

Athenex to Highlight Oral Paclitaxel Clinical Programs Targeting Various Solid Tumors at the ESMO Congress 2019

BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will present several…

Read more >

Athenex to Present at the 2019 San Antonio Breast Cancer Symposium

BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will be making an oral…

Read more >

Athenex to Present at the 2019 ASCO Annual Meeting

BUFFALO, N.Y., May 30, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will present data and…

Read more >

Athenex Announces Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting

BUFFALO, N.Y., April 23, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that four abstracts have been…

Read more >

Athenex to Present Preclinical Data of Oraxol in the Treatment of Angiosarcoma at the American Association for Cancer Research Annual Meeting 2019

BUFFALO, N.Y., March 08, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that an abstract highlighting the…

Read more >

SHOW MORE

Athenex Announces Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting

Results show that 44% and 54% of patients in studies KX01-AK-003 and KX01-AK-004, respectively, achieved 100% AK lesion clearance at Day 57 Safety profile of KX2-391 ointment may be an important competitive advantage; adherence to treatment was greater than 99% Company to host Conference Call with…

Read more >

Athenex to Host Conference Call with Key Opinion Leader Following Oral Presentation of Phase III Results of KX2-391 Ointment in the Treatment of Actinic Keratosis at the American Academy of Dermatology Annual Meeting
Seth B. Forman, MD, CEO of ForCare Medical Group and ForCare Clinical Research, to participate in a call on Monday, March 4, 2019 at 8:30am ET BUFFALO, N.Y., Feb. 25, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development…

Read more >

Athenex Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting

Results from Phase III pivotal studies to be featured at Late-Breaking Research Program on March 2, 2019 BUFFALO, N.Y., Feb. 04, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel…

Read more >

SHOW LESS

Focused on the fearless pursuit of change

  • ATHENEX PHARMACEUTICAL DIVISION (APD)
    • Sterile injectables (generics) manufactured by third-party partners all over the world
  • ATHENEX PHARMA SOLUTIONS (APS)
    • Sterile injectables made in our 503(b) outsourced compounding facility
  • POLYMED THERAPEUTICS
    • Manufacturing of APIs and chemicals, with state-of-the-art and regulatory-approved cGMP facilities and R&D laboratories